Induction of neoantigen-reactive T cells from healthy donors.


Journal

Nature protocols
ISSN: 1750-2799
Titre abrégé: Nat Protoc
Pays: England
ID NLM: 101284307

Informations de publication

Date de publication:
06 2019
Historique:
received: 20 06 2018
accepted: 21 03 2019
pubmed: 19 5 2019
medline: 11 7 2019
entrez: 19 5 2019
Statut: ppublish

Résumé

The identification of immunogenic neoantigens and their cognate T cells represents the most crucial and rate-limiting steps in the development of personalized cancer immunotherapies that are based on vaccination or on infusion of T cell receptor (TCR)-engineered T cells. Recent advances in deep-sequencing technologies and in silico prediction algorithms have allowed rapid identification of candidate neoepitopes. However, large-scale validation of putative neoepitopes and the isolation of reactive T cells are challenging because of the limited availablity of patient material and the low frequencies of neoepitope-specific T cells. Here we describe a standardized protocol for the induction of neoepitope-reactive T cells from healthy donor T cell repertoires, unaffected by the potentially immunosuppressive environment of the tumor-bearing host. Monocyte-derived dendritic cells (DCs) transfected with mRNA encoding candidate neoepitopes are used to prime autologous naive CD8

Identifiants

pubmed: 31101906
doi: 10.1038/s41596-019-0170-6
pii: 10.1038/s41596-019-0170-6
doi:

Substances chimiques

Epitopes 0
RNA, Messenger 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1926-1943

Références

Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
doi: 10.1126/science.aaa4967
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
doi: 10.1126/science.aaa4971
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4
doi: 10.1126/science.1251102
Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255–2262 (2016).
doi: 10.1056/NEJMoa1609279
Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).
doi: 10.1126/science.aaa3828
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).
doi: 10.1038/nature23003
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
doi: 10.1038/nature22991
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
doi: 10.1126/science.aaa1348
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
doi: 10.1126/science.aad0095
Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747–752 (2013).
doi: 10.1038/nm.3161
van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442 (2013).
doi: 10.1200/JCO.2012.47.7521
Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4
doi: 10.1038/nm.3773
Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).
doi: 10.1126/science.aad1253
Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
doi: 10.1038/nature13988
Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012).
doi: 10.1038/nature10755
Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014).
doi: 10.1038/nature14001
Karpanen, T. & Olweus, J. The potential of donor T-cell repertoires in neoantigen-targeted cancer immunotherapy. Front. Immunol. 8, 1718 (2017).
doi: 10.3389/fimmu.2017.01718
Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337–1341 (2016).
doi: 10.1126/science.aaf2288
Qi, Q. et al. Diversity and clonal selection in the human T-cell repertoire. Proc. Natl Acad. Sci. USA 111, 13139–13144 (2014).
doi: 10.1073/pnas.1409155111
Arstila, T. P. et al. A direct estimate of the human αβ T cell receptor diversity. Science 286, 958–961 (1999).
doi: 10.1126/science.286.5441.958
Van Tendeloo, V. F. et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98, 49–56 (2001).
doi: 10.1182/blood.V98.1.49
Ponsaerts, P. et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J. Immunol. 169, 1669–1675 (2002).
doi: 10.4049/jimmunol.169.4.1669
Hui, S. W. Effects of pulse length and strength on electroporation efficiency. Methods Mol. Biol. 55, 29–40 (1995).
pubmed: 8528420
Livingston, B. D. et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19, 4652–4660 (2001).
doi: 10.1016/S0264-410X(01)00233-X
Schubert, B. & Kohlbacher, O. Designing string-of-beads vaccines with optimal spacers. Genome Med. 8, 9 (2016).
doi: 10.1186/s13073-016-0263-6
Toussaint, N. C., Maman, Y., Kohlbacher, O. & Louzoun, Y. Universal peptide vaccines—optimal peptide vaccine design based on viral sequence conservation. Vaccine 29, 8475–8753 (2011).
doi: 10.1016/j.vaccine.2011.07.132
Pittet, M. J. et al. High frequencies of naive Melan-A/MART-1-specific CD8
doi: 10.1084/jem.190.5.705
Wolfl, M. & Greenberg, P. D. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8
doi: 10.1038/nprot.2014.064
Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520–526 (2009).
doi: 10.1038/nmeth.1345
Han, A., Glanville, J., Hansmann, L. & Davis, M. M. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol. 32, 684–692 (2014).
doi: 10.1038/nbt.2938
Tang, F. et al. RNA-seq analysis to capture the transcriptome landscape of a single cell. Nat. Protoc. 5, 516–535 (2010).
doi: 10.1038/nprot.2009.236
Davis, M. M. & Bjorkman, P. J. T-cell antigen receptor genes and T-cell recognition. Nature 334, 395–402 (1988).
doi: 10.1038/334395a0
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
doi: 10.1038/nature12213
Bentzen, A. K. et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat. Biotechnol. 34, 1037–1045 (2016).
doi: 10.1038/nbt.3662
Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511–517 (2016).
doi: 10.1093/bioinformatics/btv639
Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
doi: 10.1038/ncomms13404
Chheda, Z. S. et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J. Exp. Med. 215, 141–157 (2018).
doi: 10.1084/jem.20171046
Kalaora, S. et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8, 1366–1375 (2018).
doi: 10.1158/2159-8290.CD-17-1418
Andersen, R. S. et al. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat. Protoc. 7, 891–902 (2012).
doi: 10.1038/nprot.2012.037
Toebes, M. et al. Design and use of conditional MHC class I ligands. Nat. Med. 12, 246–251 (2006).
doi: 10.1038/nm1360
Toebes, M., Rodenko, B., Ovaa, H. & Schumacher, T. N. Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr. Protoc. Immunol. 87, 18.16.1–18.16.20 (2009).
Hadrup, S. R. et al. Cryopreservation of MHC multimers: recommendations for quality assurance in detection of antigen specific T cells. Cytometry A 87, 37–48 (2015).
doi: 10.1002/cyto.a.22575

Auteurs

Muhammad Ali (M)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Zsofia Foldvari (Z)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Eirini Giannakopoulou (E)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Maxi-Lu Böschen (ML)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Erlend Strønen (E)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Weiwen Yang (W)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Mireille Toebes (M)

Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Benjamin Schubert (B)

Institute for Biomedical Informatics, University of Tübingen, Tübingen, Germany.
Applied Bioinformatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
cBio Center, Dana-Farber Cancer Institute, Boston, MA, USA.

Oliver Kohlbacher (O)

Institute for Biomedical Informatics, University of Tübingen, Tübingen, Germany.
Applied Bioinformatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany.
Translational Bioinformatics, University Medical Center Tübingen, Tübingen, Germany.

Ton N Schumacher (TN)

Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Johanna Olweus (J)

Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway. johanna.olweus@medisin.uio.no.
K.G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. johanna.olweus@medisin.uio.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH